Hantavirus Pandemic 2026

Hantavirus pandemic 2026—where the book is right now

A May 4, 2026 hantavirus outbreak traced to the MV Hondius cruise ship has put pandemic-risk markets squarely back on the prediction market beat. Polymarket's Hantavirus pandemic in 2026? Single is the highest-volume venue on the question (~$430K traded in the last 24h, $2.7M+ all-time); the implied probability hit 32.9% on Wednesday May 6 before settling near 9% by Friday. Kalshi runs the cross-exchange mirror as a WHO Public Health Emergency of International Concern (PHEIC) declaration Single—a slightly different settlement primitive (WHO declaration vs. Polymarket's pandemic definition).

This workspace tracks the headline pandemic Singles cross-exchange, the near-term outbreak markers (outbreak confirmation, lab-leak attribution), the broader 2026 pandemic-risk Singles on both Polymarket and Kalshi, the Manifold mirror for additional liquidity-adjusted reads, and the hantavirus-vaccine tail. Markets reprice fastest on WHO declarations, CDC case counts, and any cross-border outbreak escalation.

Settlement primitives. Polymarket settles on its in-house pandemic definition; Kalshi settles on a formal WHO PHEIC declaration. The two are correlated but not identical—a WHO PHEIC requires a formal IHR Emergency Committee process, while Polymarket's market resolves on outbreak-severity criteria the platform defines independently.

Settlement source: Polymarket pandemic market · Kalshi WHO PHEIC market · WHO Disease Outbreak News

Polymarket's Hantavirus pandemic in 2026? paired with Kalshi's WHO PHEIC for hantavirus Single. Same story, two settlement primitives—pandemic-definition vs. PHEIC declaration.

The June 30 outbreak-confirmation and lab-leak attribution Singles—the near-term outbreak-pricing markets—both settled No: no confirmed secondary outbreak or lab-leak attribution by June 30, consistent with the headline probability fading from its early-May spike.

Year-level pandemic questions without the hantavirus narrowing. The spread between these and the hantavirus-specific Singles measures how much of the current pricing is hantavirus-attributable vs. baseline pandemic risk.

Manifold's mirror of the Polymarket pandemic Single is a third independent read on the headline question; the hantavirus-vaccine Single is the asymmetric-upside tail.

Cross-exchange spread on the headline Single. Polymarket's pandemic-definition market and Kalshi's WHO-PHEIC market price related but not identical questions. A persistent gap—Polymarket priced higher than Kalshi—reflects the difference in settlement criteria: it's easier to satisfy Polymarket's pandemic threshold than the WHO's PHEIC bar. When the two converge, the market is treating the two settlement bars as effectively the same.

Outbreak and lab-leak markers settled No. The June 30 outbreak-confirmation and lab-leak attribution Singles both resolved No—no confirmed secondary outbreak or lab-leak attribution by June 30—tracking the headline probability's fade from its early-May spike.

Broader 2026 pandemic-risk Singles. Kalshi's Pandemic in 2026? and Polymarket's New pandemic in 2026? price the year-level pandemic question without the hantavirus narrowing. The spread between these and the hantavirus-specific Singles measures how much of the current pricing is hantavirus-attributable vs. baseline pandemic risk.

Manifold mirror. Manifold's mirror of the Polymarket question runs at much lower volume but is useful as an independent third read—when it diverges from Polymarket by more than a few points, the Polymarket book is usually being moved by larger directional flows that haven't yet rippled to the play-money venue.

Vaccine tail. The hantavirus-vaccine-in-2026 Single is the asymmetric upside leg—low-probability priced, but the market reprices instantly on any Phase 1 trial registration or BARDA contract announcement.

News drivers to watch. WHO Disease Outbreak News updates, CDC case-count releases, additional cruise-ship or geographic-clustering reports, and any IHR Emergency Committee meeting announcement. The 2007 Polonsky et al. Clinical Infectious Diseases paper proposing prediction markets for infectious disease forecasting is the canonical academic anchor for the analytical-utility-vs-perverse-incentives debate that the news cycle is currently recapitulating around hantavirus.